Quotes 5-day view Delayed Bolsas Y Mercados Espanol
01/24/2023
01/25/2023
01/26/2023
01/27/2023
01/30/2023
Date
12.21(c)
12.365(c)
12.56(c)
12.525(c)
12.305
Last
958 474
1 136 289
1 445 994
1 090 455
493 148
Volume
-0.12%
+1.27%
+1.58%
-0.28%
-1.76%
Change
Estimated financial data (e) EUR USD
Sales 2022
5 909 M
6 415 M
6 415 M
Net income 2022
280 M
304 M
304 M
Net Debt 2022
9 355 M
10 155 M
10 155 M
P/E ratio 2022
30,5x
Yield 2022
0,42%
Sales 2023
6 716 M
7 291 M
7 291 M
Net income 2023
497 M
540 M
540 M
Net Debt 2023
8 992 M
9 761 M
9 761 M
P/E ratio 2023
16,5x
Yield 2023
0,91%
Capitalization
7 470 M
8 109 M
8 109 M
EV / Sales 2022
2,85x
EV / Sales 2023
2,45x
Nbr of Employees
27 584
Free-Float
79,8%
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:
- products derived from plasma (77.3%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (14.9%): in vitro...
All news about GRIFOLS, S.A.
News in other languages on GRIFOLS, S.A.
Analyst Recommendations on GRIFOLS, S.A.
ETFs positioned on GRIFOLS, S.A. ETFs and Trackers with Trackinsight
Grifols says U.S. blood donors' lawsuit won't have material impact, shares down
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends GRIFOLS, S.A.
Short Term Mid-Term Long Term Trends Bullish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
17
Last Close Price
12,53 €
Average target price
17,53 €
Spread / Average Target
39,9%
Please enable JavaScript in your browser's settings to use dynamic charts.